Tirzepatide vs Cagrilintide.

Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).

Cagrilintide (development code AM833) is a long-acting, once-weekly synthetic analogue of the pancreatic hormone amylin, developed by Novo Nordisk. It is a "dual amylin and calcitonin receptor agonist" (DACRA)-class peptide engineered with a lipidation (fatty-acid acylation) that prolongs its half-life, and is being investigated for chronic weight management in adults with overweight or obesity, both as a monotherapy and as the amylin component of the fixed-dose combination CagriSema (with semaglutide).

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.

Native amylin is co-secreted with insulin from pancreatic beta cells and reduces food intake by promoting meal-ending satiety, slowing gastric emptying, and suppressing glucagon. Cagrilintide mimics this by activating amylin and calcitonin receptors, which are heterodimers of the calcitonin receptor with receptor-activity-modifying proteins (RAMPs). Preclinical work in RAMP1/RAMP3 knockout mice (eBioMedicine, 2025) indicates cagrilintide's weight-lowering effect is mediated largely through brain amylin receptors 1 and 3 in hindbrain and hypothalamic circuits that govern appetite. Because amylin signaling is mechanistically distinct from GLP-1, combining the two (as in CagriSema) is intended to engage complementary satiety pathways and produce additive weight loss.

Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.

Human data are now substantial for the combination and growing for monotherapy. The pivotal phase 3 REDEFINE 1 trial in over 3,400 adults with overweight/obesity without diabetes (NEJM 2025, PMID 40544433) reported mean weight loss of roughly 20.4% with CagriSema, 11.8% with cagrilintide monotherapy, 14.9% with semaglutide, and about 3% with placebo at 68 weeks; cagrilintide thus produced clinically meaningful weight loss on its own, though less than the combination. REDEFINE 2 studied CagriSema in type 2 diabetes, and additional REDEFINE/REIMAGINE program trials (e.g., REIMAGINE 2 in The Lancet Diabetes & Endocrinology, 2026) extend the dataset. The brain-receptor mechanism evidence (eBioMedicine, PMID 40609154) is preclinical (mouse), so the molecular target attribution should not be read as proven in humans; most large efficacy data describe the semaglutide combination rather than cagrilintide alone.

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.

In the REDEFINE program the safety profile of cagrilintide and CagriSema was reported as broadly consistent with incretin/amylin-based therapies, with predominantly mild-to-moderate gastrointestinal effects (nausea, vomiting, diarrhea, constipation) as the most common adverse events, generally most pronounced during dose escalation. Long-term safety, cardiovascular outcomes, and the safety of cagrilintide as a standalone therapy are not yet fully characterized in published phase 3 data, and head-to-head long-term comparisons remain limited. As an investigational agent, cagrilintide has no established safety profile for use outside of controlled clinical trials; material sold as research-only "cagrilintide" is not a regulated medicine and carries unknown identity, purity, and contamination risks.

Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.

Cagrilintide is investigational and not approved by the FDA as a standalone drug. Novo Nordisk submitted an NDA for the CagriSema combination (cagrilintide plus semaglutide) for weight management on December 18, 2025; as of mid-2026 it remains under FDA review and is not yet approved.